This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: Bristol-Myers Squibb Compnay, E. R. Squibb Sons, Inc.. Active years: 1993-1995.
Company Filing History:
Years Active: 1993-1995
Title: David L McCann: Innovator in Pharmaceutical Technologies
Introduction
David L McCann is a notable inventor based in Merseyside, GB. He has made significant contributions to the field of pharmaceuticals, holding a total of 2 patents. His work focuses on improving drug formulations and delivery methods, which are crucial for patient care and treatment efficacy.
Latest Patents
Among his latest patents, McCann has developed a solid pharmaceutical dosage form and a method for reducing abrasion. This method involves applying a subcoat containing a pharmaceutically acceptable polyalkylene glycol to an uncoated dosage form, enhancing the durability of solid pharmaceutical products. Another significant patent is for enteric coated pharmaceutical compositions. This composition includes a medicament sensitive to low pH environments, such as pravastatin, and is designed in the form of pellets with an enteric coating made from neutralized hydroxypropylmethyl cellulose phthalate, plasticizer, and anti-adherent. These innovations ensure that the pellets maintain their integrity in acidic conditions while providing effective drug release at higher pH levels.
Career Highlights
David L McCann has worked with prominent companies in the pharmaceutical industry, including Bristol-Myers Squibb Company and E. R. Squibb Sons, Inc. His experience in these organizations has allowed him to refine his expertise in drug formulation and development.
Collaborations
Throughout his career, McCann has collaborated with notable colleagues such as Garry R Hodges and Andrew B Dennis. These partnerships have contributed to the advancement of pharmaceutical technologies and innovations.
Conclusion
David L McCann's contributions to the pharmaceutical field through his patents and collaborations highlight his role as an innovator. His work continues to impact the development of effective drug delivery systems, benefiting patients worldwide.